Impact of immunogenicity on response to anti-TNF therapy in moderate-to-severe plaque psoriasis: results of the PREDIR study.

about

Impact of immunogenicity on response to anti-TNF therapy in moderate-to-severe plaque psoriasis: results of the PREDIR study.

Item

http://www.wikidata.org/entity/Q38920322

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Impact of immunogenicity on re ...... : results of the PREDIR study.

@en

type

Item

label

Impact of immunogenicity on re ...... : results of the PREDIR study.

@en

prefLabel

Impact of immunogenicity on re ...... : results of the PREDIR study.

@en

P1476

Impact of immunogenicity on re ...... : results of the PREDIR study.

@en

P2093

Dora Pascual-Salcedo

http://www.w3.org/2001/XMLSchema#string

Mariano Ara-Martín

http://www.w3.org/2001/XMLSchema#string

Pedro Herranz Pinto

http://www.w3.org/2001/XMLSchema#string

P2860

Immunogenicity of biotherapy used in psoriasis: the science behind the scenes

Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial

Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial.

Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial.

Adalimumab elicits a restricted anti-idiotypic antibody response in autoimmune patients resulting in functional neutralisation.

Immunogenicity of monoclonal antibodies against tumor necrosis factor used in chronic immune-mediated Inflammatory conditions: systematic review and meta-analysis.

Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed.

Decreased clinical response to infliximab in ankylosing spondylitis is correlated with anti-infliximab formation.

Immunogenicity of engineered antibodies.

Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective.

P304

1-7

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/09546634.2017.1296927

http://www.w3.org/2001/XMLSchema#string

P577

2017-03-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28274164

http://www.w3.org/2001/XMLSchema#string

P921

TNF inhibitor

TNF